Semaglutide for NASH: Disappointing Results
July 2, 2022 — Nonalcoholic steatohepatitis – NASH – has yet again handed drug researchers disappointing results, this time in a study of semaglutide. Researchers presented this phase 2 study at the International Liver Congress in London last weekend. The whole point of a phase 2 study is to see if a drug works for a specific purpose. On […]
